These carriers often develop breast tumours that do not express estrogen receptor, progesterone receptor or human epidermal growth factor receptor (HER-2), resemble basal epithelia by gene expression profiles (i.e. basal subtype), and are refractory to anti-estrogen therapy, hormone therapy, and targeted therapies directed against HER-2 [36]. Here, ESR1 is linked to breast neoplasm.